Tags

Type your tag names separated by a space and hit enter

HPV genotyping from invasive cervical cancer in Chile.
Int J Gynaecol Obstet. 2009 May; 105(2):150-3.IJ

Abstract

OBJECTIVE

To determine the prevalence rates of the different HPV types in cervical cancer lesions in Chile to facilitate the development of prophylactic human papillomavirus (HPV) vaccines effective for that country.

METHOD

Biopsy samples of 312 cervical cancer lesions were assessed for HPV type by reverse-line blotting assay.

RESULTS

HPV DNA was found in 94.2% of the lesions, 67.2% harboring 1 viral type and the remainder harboring more than 1 type. HPV-16 was the most frequent type in single infections (50.5%), followed by HPV-18 (7.8%), HPV-31 (2.4%), and HPV-45 (2.0%). HPV-16 was also present in 98.7% of dual and multiple infections, its most frequent association being with HPV-18.

CONCLUSIONS

HPV types 16, 18, 31, and 45, alone or combined with other types, were observed in the biopsy samples of up to 80.5% of cervical cancer lesions.

Authors+Show Affiliations

Molecular Pathology Laboratory, Department of Pathology, Universidad de la Frontera School of Medicine, Temuco, Chile.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19249046

Citation

Roa, Juan Carlos, et al. "HPV Genotyping From Invasive Cervical Cancer in Chile." International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, vol. 105, no. 2, 2009, pp. 150-3.
Roa JC, Garcia P, Gomez J, et al. HPV genotyping from invasive cervical cancer in Chile. Int J Gynaecol Obstet. 2009;105(2):150-3.
Roa, J. C., Garcia, P., Gomez, J., Fernández, W., Gaete, F., Espinoza, A., Lepetic, A., & Suarez, E. (2009). HPV genotyping from invasive cervical cancer in Chile. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 105(2), 150-3. https://doi.org/10.1016/j.ijgo.2008.12.017
Roa JC, et al. HPV Genotyping From Invasive Cervical Cancer in Chile. Int J Gynaecol Obstet. 2009;105(2):150-3. PubMed PMID: 19249046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HPV genotyping from invasive cervical cancer in Chile. AU - Roa,Juan Carlos, AU - Garcia,Patricia, AU - Gomez,Jorge, AU - Fernández,Wanda, AU - Gaete,Fancy, AU - Espinoza,Arturo, AU - Lepetic,Alejandro, AU - Suarez,Eugenio, Y1 - 2009/02/26/ PY - 2008/11/06/received PY - 2008/12/05/revised PY - 2008/12/21/accepted PY - 2009/3/3/entrez PY - 2009/3/3/pubmed PY - 2009/7/17/medline SP - 150 EP - 3 JF - International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics JO - Int J Gynaecol Obstet VL - 105 IS - 2 N2 - OBJECTIVE: To determine the prevalence rates of the different HPV types in cervical cancer lesions in Chile to facilitate the development of prophylactic human papillomavirus (HPV) vaccines effective for that country. METHOD: Biopsy samples of 312 cervical cancer lesions were assessed for HPV type by reverse-line blotting assay. RESULTS: HPV DNA was found in 94.2% of the lesions, 67.2% harboring 1 viral type and the remainder harboring more than 1 type. HPV-16 was the most frequent type in single infections (50.5%), followed by HPV-18 (7.8%), HPV-31 (2.4%), and HPV-45 (2.0%). HPV-16 was also present in 98.7% of dual and multiple infections, its most frequent association being with HPV-18. CONCLUSIONS: HPV types 16, 18, 31, and 45, alone or combined with other types, were observed in the biopsy samples of up to 80.5% of cervical cancer lesions. SN - 1879-3479 UR - https://www.unboundmedicine.com/medline/citation/19249046/HPV_genotyping_from_invasive_cervical_cancer_in_Chile_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0020-7292(08)00608-5 DB - PRIME DP - Unbound Medicine ER -